Systemic scleroderma: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
In [[medicine]], '''systemic scleroderma''', also called '''systemic sclerosis''', is "a chronic multi-system disorder of connective tissue. | In [[medicine]], '''systemic scleroderma''', also called '''systemic sclerosis''', is "a chronic multi-system [[connective tissue disease|disorder of connective tissue]]. It is characterized by sclerosis in the skin, the lungs, the heart, the gastrointestinal tract, the kidneys, and the musculoskeletal system. Other important features include diseased small blood vessels and autoantibodies. the disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: limited scleroderma and diffuse scleroderma."<ref>{{MeSH}}</ref> | ||
==Complications== | ==Complications== | ||
===Renal crisis== | ===Renal crisis=== | ||
With treatment using [[angiotensin-converting enzyme inhibitor]]s, only 4% progress to renal failure and [[renal dialysis]] after 5 to 10 years.<ref name="pmid11033587">{{cite journal| author=Steen VD, Medsger TA| title=Long-term outcomes of scleroderma renal crisis. | journal=Ann Intern Med | year= 2000 | volume= 133 | issue= 8 | pages= 600-3 | pmid=11033587 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11033587 }} </ref> | With treatment using [[angiotensin-converting enzyme inhibitor]]s, only 4% progress to renal failure and [[renal dialysis]] after 5 to 10 years.<ref name="pmid11033587">{{cite journal| author=Steen VD, Medsger TA| title=Long-term outcomes of scleroderma renal crisis. | journal=Ann Intern Med | year= 2000 | volume= 133 | issue= 8 | pages= 600-3 | pmid=11033587 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11033587 }} </ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 10:38, 9 March 2012
In medicine, systemic scleroderma, also called systemic sclerosis, is "a chronic multi-system disorder of connective tissue. It is characterized by sclerosis in the skin, the lungs, the heart, the gastrointestinal tract, the kidneys, and the musculoskeletal system. Other important features include diseased small blood vessels and autoantibodies. the disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: limited scleroderma and diffuse scleroderma."[1]
Complications
Renal crisis
With treatment using angiotensin-converting enzyme inhibitors, only 4% progress to renal failure and renal dialysis after 5 to 10 years.[2]
References
- ↑ Anonymous (2024), Systemic scleroderma (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Steen VD, Medsger TA (2000). "Long-term outcomes of scleroderma renal crisis.". Ann Intern Med 133 (8): 600-3. PMID 11033587. [e]